Journal Article

Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US

Cohet, Catherine, Prieto-Alhambra, Daniel, Li, Xintong, Duarte-Salles, Talita, Mayer, Miguel-Angel, Verhamme, Katia, Li, Kelly, Strauss, Victoria, Rijnbeek, Peter, Delmestri, Antonella, John, Luis H, Mosseveld, Mees, Ramirez-Anguita, Juan-Manuel, Yin, Can, Reich, Christian, Suchard, Marc A, Burn, Edward

2022

Overview

AbstractObjectiveTo quantify the comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with use of adenovirus based covid-19 vaccines versus mRNA based covid-19 vaccines.DesignInternational network cohort study.SettingRoutinely collected health data from contributing datasets in France, Germany, the Netherlands, Spain, the UK, and the US.ParticipantsAdults (age ≥18 years) registered at any contributing database and who received at least one dose of a covid-19 vaccine (ChAdOx1-S (Oxford-AstraZeneca), BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), or Ad26.COV2.S (Janssen/Johnson & Johnson)), from December 2020 to mid-2021.Main outcome measuresThrombosis with thrombocytopenia syndrome or venous or arterial thromboembolic events within the 28 days after covid-19 vaccination. Incidence rate ratios were estimated after propensity scores matching and were calibrated using negative control outcomes. Estimates specific to the database were pooled by use of random effects meta-analyses.ResultsOverall, 1 332 719 of 3 829 822 first dose ChAdOx1-S recipients were matched to 2 124 339 of 2 149 679 BNT162b2 recipients from Germany and the UK. Additionally, 762 517 of 772 678 people receiving Ad26.COV2.S were matched to 2 851 976 of 7 606 693 receiving BNT162b2 in Germany, Spain, and the US. All 628 164 Ad26.COV2.S recipients from the US were matched to 2 230 157 of 3 923 371 mRNA-1273 recipients. A total of 862 thrombocytopenia events were observed in the matched first dose ChAdOx1-S recipients from Germany and the UK, and 520 events after a first dose of BNT162b2. Comparing ChAdOx1-S with a first dose of BNT162b2 revealed an increased risk of thrombocytopenia (pooled calibrated incidence rate ratio 1.33 (95% confidence interval 1.18 to 1.50) and calibrated incidence rate difference of 1.18 (0.57 to 1.8) per 1000 person years). Additionally, a pooled calibrated incidence rate ratio of 2.26 (0.93 to 5.52) for venous thrombosis with thrombocytopenia syndrome was seen with Ad26.COV2.S compared with BNT162b2.ConclusionsIn this multinational study, a pooled 30% increased risk of thrombocytopenia after a first dose of the ChAdOx1-S vaccine was observed, as was a trend towards an increased risk of venous thrombosis with thrombocytopenia syndrome after Ad26.COV2.S compared with BNT162b2. Although rare, the observed risks after adenovirus based vaccines should be considered when planning further immunisation campaigns and future vaccine development.

• Publisher: British Medical Journal Publishing Group,BMJ Publishing Group LTD
• Subject: Adenoviruses / Ambulatory care / Clinical medicine / Cohort analysis / Collaboration / Comorbidity / Coronaviruses / COVID-19 vaccines / Datasets / Drug dosages / Electronic health records / Hospitals / Information systems / Ischemia / Medical records / mRNA / Practice research / Primary care / Pulmonary embolisms / Severe acute respiratory syndrome coronavirus 2 / Thrombocytopenia / Thromboembolism / Thrombosis / Vaccine development / Vaccines / Veins & arteries